X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs SUN PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD SUN PHARMA BIOCON LTD/
SUN PHARMA
 
P/E (TTM) x 36.6 15.3 238.8% View Chart
P/BV x 4.9 3.6 135.0% View Chart
Dividend Yield % 1.5 0.2 715.0%  

Financials

 BIOCON LTD   SUN PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-16
SUN PHARMA
Mar-16
BIOCON LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs4961,201 41.3%   
Low Rs397706 56.1%   
Sales per share (Unadj.) Rs174.3117.5 148.4%  
Earnings per share (Unadj.) Rs44.819.6 228.6%  
Cash flow per share (Unadj.) Rs56.923.8 239.1%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %1.10.1 1,068.8%  
Book value per share (Unadj.) Rs202.8130.5 155.4%  
Shares outstanding (eoy) m200.002,406.60 8.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.68.1 31.5%   
Avg P/E ratio x10.048.7 20.5%  
P/CF ratio (eoy) x7.840.1 19.6%  
Price / Book Value ratio x2.27.3 30.1%  
Dividend payout %11.25.1 218.7%   
Avg Mkt Cap Rs m89,2202,294,813 3.9%   
No. of employees `0004.414.7 29.9%   
Total wages/salary Rs m6,36347,971 13.3%   
Avg. sales/employee Rs Th7,894.519,169.8 41.2%   
Avg. wages/employee Rs Th1,441.23,253.0 44.3%   
Avg. net profit/employee Rs Th2,029.73,197.9 63.5%   
INCOME DATA
Net Sales Rs m34,854282,697 12.3%  
Other income Rs m8456,170 13.7%   
Total revenues Rs m35,699288,867 12.4%   
Gross profit Rs m8,20083,239 9.9%  
Depreciation Rs m2,42310,135 23.9%   
Interest Rs m1024,769 2.1%   
Profit before tax Rs m6,52074,505 8.8%   
Minority Interest Rs m-744-11,126 6.7%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m5,754-6,852 -84.0%   
Tax Rs m2,5699,349 27.5%   
Profit after tax Rs m8,96147,159 19.0%  
Gross profit margin %23.529.4 79.9%  
Effective tax rate %39.412.5 314.0%   
Net profit margin %25.716.7 154.1%  
BALANCE SHEET DATA
Current assets Rs m39,932308,646 12.9%   
Current liabilities Rs m16,276132,477 12.3%   
Net working cap to sales %67.962.3 108.9%  
Current ratio x2.52.3 105.3%  
Inventory Days Days5483 64.6%  
Debtors Days Days8688 98.2%  
Net fixed assets Rs m39,101133,606 29.3%   
Share capital Rs m1,0002,407 41.6%   
"Free" reserves Rs m38,591266,909 14.5%   
Net worth Rs m40,556314,042 12.9%   
Long term debt Rs m20,72431,167 66.5%   
Total assets Rs m84,816542,196 15.6%  
Interest coverage x64.916.6 390.6%   
Debt to equity ratio x0.50.1 514.9%  
Sales to assets ratio x0.40.5 78.8%   
Return on assets %10.79.6 111.6%  
Return on equity %22.115.0 147.1%  
Return on capital %19.017.8 106.9%  
Exports to sales %30.714.0 219.7%   
Imports to sales %20.43.1 648.8%   
Exports (fob) Rs m10,71739,572 27.1%   
Imports (cif) Rs m7,1058,882 80.0%   
Fx inflow Rs m11,78942,171 28.0%   
Fx outflow Rs m8,39321,583 38.9%   
Net fx Rs m3,39620,588 16.5%   
CASH FLOW
From Operations Rs m5,26467,694 7.8%  
From Investments Rs m-9,540-44,549 21.4%  
From Financial Activity Rs m10,867-19,243 -56.5%  
Net Cashflow Rs m6,5913,902 168.9%  

Share Holding

Indian Promoters % 40.4 63.7 63.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.1 163.7%  
FIIs % 10.7 23.0 46.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.3 239.8%  
Shareholders   109,995 133,026 82.7%  
Pledged promoter(s) holding % 0.0 0.5 7.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS